Injectable poly-L-lactic acid for cosmetic enhancement: Learning from the European experience

被引:46
作者
Butterwick, Kimberly [1 ]
Lowe, Nicholas J. [2 ,3 ]
机构
[1] La Jolla Inc, Dermatol Cosmet Laser Associates, La Jolla, CA 92037 USA
[2] Cranley Clin, London, England
[3] Cranley Clin, Santa Monica, CA USA
关键词
SOFT-TISSUE AUGMENTATION; FACIAL LIPOATROPHY; POLYLACTIC ACID; OPEN-LABEL; INJECTIONS; EFFICACY; SAFETY; FILLER;
D O I
10.1016/j.jaad.2008.11.881
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Currently a diverse range of injectable agents are used for noninvasive facial enhancement. Injectable poly-L-lactic acid (PLLA) is a biocompatible, biodegradable, synthetic polymer that is approved for correction of HIV-related facial lipoatrophy in Europe, Canada, and the United States. PLLA is also approved in several countries for cosmetic purposes, and is under review in the United States for this indication. After injection, PLLA elicits a gradual increase in facial volume via hypothesized endogenous production of fibroblasts and, subsequently, collagen, enabling global facial rejuvenation to be tailored, as required, over time. Substantial increases in dermal thickness after injection of PLLA have been observed to last for up to 2 years. This article reviews the use of PLLA in Europe and the United States with regard to practitioner experiences and techniques for optimizing Outcomes. Correct reconstitution and administration of PLLA have been found to be important parameters for optimal use of this agent. (J Am Acad Dermatol 2009;61:281-93.)
引用
收藏
页码:281 / 293
页数:13
相关论文
共 36 条
[1]  
*AM AC FAC PLAST R, 2006 MEMB SURV TREND
[2]  
Andre P, 2005, J Cosmet Laser Ther, V7, P171, DOI 10.1080/14764170500344393
[3]   Full scope of effect of facial lipoatrophy: A framework of disease understanding [J].
Ascher, Benjamin ;
Coleman, Sydney ;
Alster, Tina ;
Bauer, Ute ;
Burgess, Cheryl ;
Butterwick, Kimberly ;
Donofrio, Lisa ;
Engelhard, Peter ;
Goldman, Mitchel P. ;
Katz, Philippe ;
Vleggaar, Danny .
DERMATOLOGIC SURGERY, 2006, 32 (08) :1058-1069
[4]  
Bauer U, 2004, IMPROVEMENT FACIAL A
[5]  
Bergeret-Galley Catherine, 2004, Aesthet Surg J, V24, P33, DOI 10.1016/j.asj.2004.01.006
[6]   Polylactic acid injections (Newfill®) in the treatment of facial lipoatrophy in HIV-positive patients [J].
Bodokh, I. ;
Simonet, P. .
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2006, 133 (05) :429-432
[7]   Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients [J].
Borelli, C ;
Kunte, C ;
Weisenseel, P ;
Thoma-Greber, E ;
Korting, HC ;
Konz, B .
SKIN PHARMACOLOGY AND PHYSIOLOGY, 2005, 18 (06) :273-278
[8]   An overview of permanent and semipermanent fillers [J].
Broder, Kevin W. ;
Cohen, Steven R. .
PLASTIC AND RECONSTRUCTIVE SURGERY, 2006, 118 (03) :7S-14S
[9]   Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy [J].
Burgess, CM ;
Quiroga, RM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (02) :233-239
[10]  
*DERM LAB, 2006, SCULPTR PROD INF